Table 2 Values of outcome measures by treatment group and time of measurement
| Â | Â | CDT | CT |
|---|---|---|---|
Outcome measure | Time of measurement | Mean ± SD (95 % CI) | Mean ± SD (95 % CI) |
VAS | Baseline | 6.87 ± 0.94 (6.52–7.22) | 6.90 ± 1.09 (6.49–7.31) |
4th Week | 3.17 ± 0.87 (2.84–3.49) | 4.53 ± 1.07 (4.13–4.93) | |
6th Week | 1.40 ± 0.50 (1.21–1.59) | 2.93 ± 0.87 (2.61–3.26) | |
EORTC QLQ C30 Global scale | Baseline | 39.60 ± 4.74 (37.83–41.37) | 39.63 ± 4.71 (37.81–41.39) |
4th Week | 41.9 ± 4.72 (40.14–43.66) | 40.57 ± 4.72 (38.80–42.33) | |
6th Week | 49.13 ± 5.49 (47.08–51.18) | 41.57 ± 4.72 (39.80–43.33) | |
EORTC QLQ C30 Functional scale | Baseline | 79.93 ± 1.41 (79.41–80.46) | 79.93 ± 1.41 (79.41–80.46) |
4th Week | 83.27 ± 1.98 (82.53–84.01) | 80.87 ± 1.36 (80.36–81.37) | |
6th Week | 85.27 ± 1.98 (84.53–86.01) | 81.83 ± 1.42 (81.30–82.36) | |
EORTC QLQ C30 Symptoms scale | Baseline | 40.93 ± 3.26 (39.72–42.15) | 40.93 ± 3.26 (39.72–42.15) |
4th Week | 44.07 ± 3.42 (42.79–45.34) | 41.93 ± 3.26 (40.72–43.15) | |
6th Week | 47.07 ± 3.51 (45.75–48.38) | 42.90 ± 3.32 (41.66–44.14) | |
EORTC QLQ BR23 Functional scale | Baseline | 32.20 ± 2.11 (31.41–32.99) | 32.20 ± 2.11 (31.41–32.99) |
4th Week | 36.37 ± 2.54 (35.42–37.31) | 33.20 ± 2.11 (32.41–33.99) | |
6th Week | 38.13 ± 2.71 (37.12–39.15) | 34.17 ± 2.20 (33.35–34.99) | |
EORTC QLQ BR23 Symptoms scale | Baseline | 58.67 ± 2.34 (57.79–59.54) | 58.67 ± 2.34 (57.79–59.54) |
4th Week | 62.33 ± 2.52 (61.39–63.28) | 59.67 ± 2.34 (58.79–60.54) | |
6th Week | 62.63 ± 7.99 (59.55–65.52) | 60.63 ± 2.40 (59.74–61.53) |